Viromed Medical AG Achieves Milestone in Multinational Collaboration

Viromed Medical AG has reached a significant milestone in its collaboration with a multinational corporation, as announced on 28 February 2025. This partnership involves granting Viromed a European license for utilizing cold atmospheric pressure plasma in medicine. This licensing allows Viromed to produce ViroCAP® systems for dermatological applications under the Medical Device Regulation framework.

Additionally, Viromed exclusively holds intellectual property rights related to the PulmoPlas® system used in pulmonary medicine. The production of both the ViroCAP® and PulmoPlas® systems will be managed by relyon plasma GmbH, a subsidiary of TDK Electronics AG.

Special approval for PulmoPlas® from the Federal Institute for Drugs and Medical Devices is anticipated in Q3 2025. Viromed is proceeding with classifying ViroCAP® as a class 2a medical device and has commenced its series production.